1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

Memorial Sloan-Kettering Cancer Center andWeill Cornell Medical CollegeCurriculum vitae and BibliographyDate of preparation: February 8, 2013A. GENERAL INFORMATION1. Name/Degree(s) Renier Joseph Brentjens2. Institution Name, Office address: 1275 York AveSchwartz 713, Box# 242New York, NY 10065Office telephone: 212-639-7053Office fax: 212-772-84413. Beeper: 917-556-7506 #41904. Email: brentjer@mskcc.org5. Citizenship: United StatesThe Netherlands6. Optional Information:a. Languages spoken/written English and Dutchb. Gender MaleB. EDUCATIONAL BACKGROUND1. Degree(s)(Undergraduate and above), institution name and location, dates attended, and date(s) ofdegree(s) awarded (in chronological order beginning with undergraduate degree or equivalent).Degree Institution name and location Dates attended Year AwardedBA HistoryMAMicrobiologyPhDMicrobiologyMDDavidson College, Davidson, NorthCarolinaState University of New York (SUNY)At Buffalo, Buffalo, NYState University of New York (SUNY)At Buffalo, Buffalo, NYState University of New York (SUNY)At Buffalo, Buffalo, NY1985–1989 19891989–1996 19941989–1996 19961989–1996 1996C. PROFESSIONAL POSITIONS AND EMPLOYMENT(In chronological order beginning with post-doctoral training positions: include full titles, ranks andinclusive dates held)1

1. Post-doctoral training including residency/fellowshipTitle Institution name and location DatesIntern/ResidentFellowFellowDepartment of Internal Medicine, Yale NewHaven Hospital, New Haven, CTDepartment of Medical Oncology, MemorialSloan Kettering Cancer Center, New York,NYDepartment of Medicine, Weill MedicalCollege of Cornell University1996-19981998-20021998-20022. Academic positions (teaching and research)Title Institution name and location DatesInstructorInstructorAssistant Member (Level 1)(NB:same rank as Clinical Assistant,but title changed to above rank in2004)Assistant MemberAssistant Professor of MedicineAssociate MemberAssociate Professor of MedicineChiefMemorial Sloan Kettering Cancer Center,New York, NYWeill Medical College of Cornell University,New York, NYMemorial Sloan Kettering Cancer Center,New YorkMemorial Sloan Kettering Cancer Center,New YorkWeill Cornell Medical College of CornellUniversity, New York, NYMemorial Sloan Kettering Cancer Center,New York, NYWeill Cornell Medical College of CornellUniversity, New York, NYCellular Therapeutics Center (CTC),Memorial Sloan Kettering Cancer Center,New York, NY2002-20032002-20072004-20072007-20112007-20112011-present2011-present2012-present2

3. Hospital positions (e.g., attending physician)Title Institution name and location DatesInstructorAssistant AttendingAssistant AttendingAssociate AttendingAssociate Attending4. Other Employment NONEDepartment of Medicine, Leukemia Service,Memorial Hospital for Cancer and AlliedDiseases, New York, NYDepartment of Medicine, Leukemia Service,Memorial Hospital for Cancer and AlliedDiseases, New York, NYDepartment of Clinical Laboratories,Hematology Laboratory Service, MemorialHospital for Cancer and Allied Diseases,New York, NYDepartment of Medicine, Leukemia Service,Memorial Hospital for Cancer and AlliedDiseases, New York, NYDepartment of Clinical Laboratories,Hematology Laboratory Service, MemorialHospital for Cancer and Allied Diseases,New York, NY2002-20032003-20112004-20112011-present2011-presentTitle Institution name and location Dates5. Breaks in academic or medically-related employment of one month or longerD. LICENSURE, BOARD CERTIFICATION, MALPRACTICE1. LicensureState Number Date of issue Date of expirationNew York 209957-1 11/1/2007 10/31/2013If no license:a. Do you have a temporary certificate?b. Have you passed the examination for foreign medicalschool graduates?Number Date of issue Date of expirationDEA: BB5848772 6/7/2010 7/31/20133

NPI: 15886355102. Board Certification(s)Full Name of Board Candidate # Year passed Year expires/dABIM – Internal Medicine 195577 1999ABIM – Medical Oncology 195577 2002 2002(scheduled forrecertificationexam 4/2013)NYS DOH Cert. of Qualification(Cellular Immunology)3. Malpractice insuranceCQ code:BRENR22005Do you have Malpractice insurance?Name of Provider:Premiums paid by:YesMSK Insurance, US, IncMemorial Sloan-Kettering Cancer CenterE. PROFESSIONAL MEMBERSHIPSMember/officer/other Name of Organization DatesMember American Society of Microbiology 1991-1995Member American College of Physicians (ACP) 1997-presentMember American Society of Clinical Oncology (ASCO) 1999-presentMember American Society of Hematology (ASH) 2000-presentMemberMemberAmerican Society of Gene and Cell Therapy(ASGCT formerly ASGT)International Society of Analytical Cytology(ISAC)2002-present2002-presentMember New York Academy of Sciences 2009-presentMember American Association for Cancer Research 2011-presentF. HONORS AND AWARDSName of awardDate awardedUndergraduate (Davidson College)4

Kendrick Kelly History Scholar 1988Alpha Epsilon Delta Honor Society 1988Phi Beta Kappa Honor Society 1989Cum Laude Degree with Honors in History 1989Graduate (SUNY at Buffalo)First Prize Student Research Forum 1990Summer Research Fellowship Award 1990, 1991American Society of Microbiology Student Travel Grant 1994Post-Graduate (MSKCC)Lauri Strauss Foundation Fellow 1999-2000Errol and Gladys Cook Fellow, Cure for Lymphoma Foundation 2000-2002Doris Duke Translations Research Grant Award Recipient 2001Physician Scientist Development Award (MSKCC) 2004Amgen Career Development Award 2005-2008Damon Runyon Clinical Investigator Award 2006-2011Outstanding New Investigator (ASGCT) 2009G. INSTITUTIONAL/HOSPITAL AFFILIATIONPrimary Hospital Affiliation:Other Hospital Affiliations:Other Institutional Affiliations:Memorial Hospital for Cancer and Allied DiseasesWeill Cornell Medical CollegeH. EMPLOYMENT STATUSName of Employer(s): Memorial Sloan-Kettering Cancer CenterEmployment Status: Full-time salariedI. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND EFFORT1. Teaching/Mentoring (e.g., specific teaching and mentoring activities, courses taught, dates)ActivityDatesFaculty, Clinical Methodology Curriculum (MSKCC) 11/24/200311/07/200503/08/200802/08/2010Attending Rounds during in-patient duties on the Leukemia Service2002-present5

Training of Medical Oncology Fellows in Clinic and During InpatientService TimeFaculty, Molecular Pharmacology of Cancer, Department of Pharamacology, WeillGraduate School of Medical SciencesMentoring in laboratory of High School, College, and Medical Students,Internal Medicine House-Staff (WMC), Medical and Pediatric OncologyFellows and Post-Doctoral FellowsHouse-Staff Noon-Time Lectures (MSKCC)2002-present2004-20122004-present2006-presentMentorshipJames Lee MD; Role: Medical Student; Current Position: Instructor,Department of Medicine, MSKCC, New York, NY06/2004-06/2009Alena Chekmasova PhD; Role: Post Doc; Current Position: N/A 04/2008-05/2012Kevin Curran MD; Role: Pediatric Oncology Fellow; Current Position:Still Working in Lab/Instructor, Department of Pediatrics, MSKCC, NewYork, NYJae Park MD; Role: Medical Oncology Fellow; Current Position: AssistantAttending Physician, Leukemia Service, MSKCC, New York, NYErik Hayman; Role: Howard Hughes Training Fellow; Current Position:N/AHollie Pegram PhD; Role: Post Doc; Current Position: Still Working in theLab; MSKCC, New York, NYSamith Sandadi MD; Role: GYN Oncology Fellow; Current Position:Fellow at MSKCC, New York, NYPeter Chang; Role: Immunology Graduate Student; Current Position: StillWorking the Lab, MSKCC, New York, NYStephen Lee MD; Role: GYN Oncology Fellow; Current Position: StillWorking in the Lab; MSKCC, New York, NYLiora Schultz MD; Role: Pediatric Fellow; Current Position: Still Workingin the Lab, MSKCC, New York, NYMythili Koneru MD PhD; Role: GYN Oncology Fellow; Current Position:Still Working in the Lab, MSKCC, New York, NY06/2008-present06/2009-07/201106/2009-07/201001/2010-present06/2010-06/201202/2011-present07/2011-present09/2011-present06/2012-present6

Sarwish Rafiq PhD; Role: Post Doc Fellow; Current Position: StillWorking in the Lab, MSKCC, New York, NYSwati Pendharkar MD: Role: Research Fellow; Current Position: StillWorking in the lab, MSKCC, New York, NY06/2012-present07/2012-present2. Clinical CareActivityAttending, Outpatient Clinic, Leukemia Service, ½ day per weekAttending, Inpatient Leukemia Service, 8-12 Weeks AnnuallyDates2002-present2002-present3. Administrative dutiesActivityAssociate Director, Cell Mark Laboratory, MSKCCMember, Investigational New Drug (IND) Committee, MSKCCMember, Pharmacy and Therapeutics Committee, MSKCCAssociate Medical Director, Cytotherapy Laboratory, MSKCCMember, Executive Committee, Memorial Hospital Alumni Society,MSKCC (President 2012-13)Member; GMP Working Committee, MSKCCMember, Special Prizes and Awards (SPA) Committee, MSKCCMember, Institutional Bio-safety Committee (IBC) Committee, MSKCCDates2004-present2007-present2008-present2009-present2009-present2011-present2012-present2012-present4. ResearchT cells may be genetically modified to express tumor targeted artificial T cell receptors, termedchimeric antigen receptors (CARs), through retroviral mediated gene transfer. Resulting CARmodified T cells now recognize tumor cells with the capacity to lyse these tumor cells, Using thistechnology our lab has generated a both pre-clinical as well as translational research programwherein we investigate the biology of these CAR modified T cells both in clinically relevantmurine models of disease as well as through currently ongoing clinical trials. To date we haveinvestigated CAR modified T cells targeted to the CD19 antigen expressed on most B cellmalignancies both in preclinical as well as clinical trial studies. Additionally we are investigatingthe potential of CAR modified T cells targeted to ovarian cancer antigens as well as the moreubiquitous WT-1 cancer antigen.7

Summary of the above time and effortCurrent PercentEffort (%)Does the activity involveWCMC students and/orresearchers? (Y/N)Does the activity involveMSKCC trainees and/orresearchers? (Y/N)Teaching/Mentoring 15% Y YClinical Care 20% Y YAdministration 5% N NResearch 60% N NTOTAL 100%J. RESEARCH SUPPORT(Summarize [in chronological order] past research support and list the following for current extramural andintramural research funding)1. Title of grant, source, amount, and duration of support (dates)2. Name of Principal Investigator3. Individual’s role in project, including percent (%) effortACTIVER01 Award (CA138738-01) (PI:Brentjens)04/1/2009-03/31/14NCI$200,000 (Annually)Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cellsNCI STRAP Supplemental Award (3R01CA138738-02S1)(PI: Brentjens)NCINo Time Limit on Duration isRequired of this Award$1,951,470Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cellsWilliam Lawrence Blanche Hughes Foundation Grant (PI:Brentjens)William Lawrence Blanche Hughes Foundation1 year with potentialadditional funding for afurther 2 years ($150,000annually plus a one timeaward of $1,800,000 (2012)Adoptive Therapy with CD19 Targeted EBV-specific Donor T Cells in Pediatric Patientswith Relapsed B cell ALLCLL Global Research Foundation Research Grant(PI: Brentjens)CLL Global Research Foundation04/01/09-03/31/14$100,000(Annually)A phase I clinical trial of consolidation therapy with autologous T cells genetically targetedto the CD19 antigen in high risk CLL patients following upfront chemotherapy withpentostatin, cyclophosphamide, and rituximab35%5%5%5%8

Experimental Therapeutics Center Program Project Grant(Project 4) (Project 4 PI:Brentjens)MSKCCMultimodal Cure of ALLCOMPLETED (within past three years)04/01/09-03/31/14$180,000(Annually)10%Geoffrey Beene Cancer Research Fund Award (PI: 12/1/2007 - 11/30/2009Brentjens)$130,000 (Annually)Genetic Modifications to enhance the in vivo survival and Anti-Tumor Activity of GeneModified CD19-Targeted T cellsExperimental Therapeutics Center Grant (Project 1 PI:Brentjens)MSKCC6/1/2005 - 5/31/2010$95,000 (Annually)In vitro and In vivo Pre-Clincal Analysis of ALL and MCL patient -derived tumor targeted TcellsTranslational and Integrative Medicine Fund Research 1/1/08 - 12/31/2010Grant (PI: Brentjens)$150,000 (Annually)Development of a novel approach to the treatment of Advanced Ovarian Cancer UtilizingAutologous T Cells Targeted to the MUC-16 AntigenDamon Runyon Clinical Investigator Award (PI: Brentjens) 7/1/2006 - 6/30/2011Damon Runyon Foundation$150,000 (Annually)Adoptive Therapy of B cell Leukemias with Genetically Modified Autologous T Cells15%10%20%MENTEE AWARDSGC219368 (PI: Schultz)(Mentor: Brentjens)7/1/2012 - 6/30/2014St. Baldrick's Foundation$92,391Improving Outcomes in Pediatric Leukemia using Adoptive ImmunotherapyK. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES(e.g., Invited lectures, Journal reviewer, NIH study section, etc)Invited lecturesDateLecture and venue11/1/03-11/06/03 Salzburg Medical Seminars Oncology 2003. Faculty Member, Salzburg, Austria6/10/2004 “Targeting Leukemia with Genetically Enhanced T Lymphocytes”, TranslationalResearch Seminar Series, Memorial Sloan-Kettering Cancer Center, New York,NY2/15/2006 Hematology/Oncology Grand Rounds New York Presbyterian Hospital, WeillMedical College, New York, NY9

5/3/2006 “Adoptive therapy with genetically modified T cells for the treatment of B cellmalignancies”, Experimental Therapeutics Center Retreat, Memorial Sloan-Kettering Cancer Center, New York, NY6/3/2006 Moderator, Oral Abstract Session: Cancer-Immunotherapy: Lymphocyte Targetsfor Gene Therapy, American Society of Gene Therapy 9 th Annual Meeting,Baltimore MD9/9/06-9/16/06 Salzburg Medical Seminars - Oncology 2006. Faculty Member, Salzburg, Austria11/7/2006 Immunology Seminar, Roswell Park Cancer Institute, Buffalo NY11/8/2006 Microbiology/Immunology Seminar, SUNY at Buffalo, Buffalo NY1/10/2007 Hematology/Oncology Grand Rounds University of Medicine and Dentistry ofNew Jersey, Newark NJ2/26/2007 “Adoptive therapy with genetically modified T cells for the treatment of B cellmalignancies”, Nuclear Medicine Grand Rounds, Memorial Sloan-KetteringCancer Center, New York, NY3/13/2007 Immunology Seminar, University of Miami Sylvester Comprehensive CancerCenter, Miami FL4/27/2007 “Adoptive T cell therapy of cancer: From the bench-top to the bedside”,Department of Medicine Grand Rounds, Memorial Sloan-Kettering CancerCenter, New York, NY5/1/2007 “Adoptive therapy with genetically modified T cells for the treatment of B cellmalignancies”, Clinical Laboratories Grand Rounds, Memorial Sloan-KetteringCancer Center, New York, NY9/27/2007 “Adoptive therapy with genetically modified T cells for the treatment of B cellmalignancies”, Takara Biotechnology Inc Research Seminar. Kyoto, Japan9/29/2007 “Adoptive therapy with genetically modified T cells for the treatment of B cellmalignancies”, The 4 th Nikko International Symposium, Jichi Medical University,Tochigi, Japan1/6/2008 “Genetically modified autologous T cells targeted to the CD19 antigen: A clinicaltrial in patients with chemotherapy refractory CLL.”, Center for Cell EngineeringInaugural Retreat, Memorial Sloan-Kettering Cancer Center, New York, NY9/9/2008 “Genetically modified T cells for adoptive therapy of cancer: Pre-clinical models,the tumor microenvironment, and the design of future clinical trials”, HematologyOncology Grand Rounds, Memorial Sloan-Kettering Cancer Center, New YorkNY10/1/2008 Immunology Seminar, Washington University, St. Louis MO10

3/29/2009 “Adoptive T cell therapy of B cell malignancies: Of mice and men”, ATTACK,2nd Cellular Therapy of Cancer Symposium, Milan, Italy5/28/2009 “Treatment of B cell malignancies with CD19-targeted T cells”, AmericanSociety of Gene Therapy Annual Meeting, Outstanding New InvestigatorSymposium, San Diego CA10/28/2009 “Adoptive cell therapy of cancer utilizing genetically targeted T cells: Addressingthe hostile tumor microenvironment”, Critical Frontiers Between Immunity andGene Therapy, International symposium, Pamplona, Spain11/16/2009 “Treatment of B cell malignancies with CD-19 targeted T cells” ImmunologyResearch Conference, CUNY Hunter College, New York, NY11/18/2009 “Initial results from a phase I clinical trial treating chemotherapy refractorychronic lymphocytic leukemia patients with autologous CD19-targeted T cells”,Cold Spring Harbor Laboratories Symposia: In Vivo Barriers to Gene Delivery,Cold Spring Harbor, NY6/15/2010 “Serious Adverse Events in Trials Utilizing Chimeric Antigen Receptors: Lessonsfor Trial Design.” National Institutes of Health, Office of BiotechnologyActivities Symposia: Gene Modified T cells: Challenges in Clinical Trial Design,Rockville MA8/3/2010 “Adoptive T cell therapy of B cell malignancies: Of mice and men”, Departmentof Microbiology and Immunology Seminar, Dartmouth Medical School, Lebanon,NH09/26/2010 “CAR modified T cells, lymphodepletion, and the hostile tumormicroenvironment: Where do we go from here?”, ATTACK, 3rd Cellular Therapyof Cancer Symposium, Montpellier, France3/3/2011 “A multi-center clinical consortium to investigate the biology and clinical efficacyof autologous T cells genetically targeted to the CD19 antigen in patients with Bcell malignancies”, Clinical Trials and Translational Research AdvisoryCommittee 13 th Meeting, National Cancer Institute, Bethesda, MD3/8/2011 “Adoptive cell therapy of caner: Building a better T cell”, Hematology/OncologyGrand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY3/10/2011 “Adoptive T cell Therapies targeting CD19+ malignancies , from mouse modelsto clinical translation”, Translational Research Seminar Series, Memorial Sloan-Kettering Cancer Center, New York, NY4/10/2011 “Genetically targeted T cells further modified to secrete IL-12 exhibit enhanced invivo eradication of targeted cells in the absence of prior lymphodepletion” ColdSpring Harbor Laboratory Stem Cell Engineering and Cell-Based TherapiesMeeting, Cold Spring Harbor, NY11

5/18/2011 “Adoptive Therapy of Cancer with T cells Genetically Targeted to TumorAssociated Antigens through the Introduction of Chimeric Antigen Receptors(CARs): Trafficking, Persistence, and Perseverance”, American Society of Geneand Cell Therapy 14 th Annual Meeting, Seattle, WA6/1/2011 “Adoptive Therapy of Cancer using Genetically Targeted T cells: EnhancingCAR design, preclinical studies, translation to the clinical setting, and addressingthe tumor microenvironment", Preston Robert Tisch Brain Tumor Center Seminar,Duke University, Durham, NC10/19/2011 “Adoptive T-cell Therapy of Cancer from the Bench Top to the Bedside andBeyond”, 2 nd Annual Asian Cellular Therapy Organization, Miyazaki, Japan10/21/2011 “Genetically Modified T cells for Cancer Therapy: Building the Perfect T cell”,National Cancer Center, Tokyo, Japan12/21/2011 “Adoptive therapy of B cell malignancies with genetically targeted T cells: Fromthe bench top to the bedside and back again”, Dana-Farber Cancer Institute,Boston, MA2/24/2012 “Chimeric Antigen Receptors (CARs): Adoptive therapy of B cell malignanciesutilizing CD19 targeted CAR modified T cells” Keynote Lecture, 16 th AnnualInternational Congress on Hematologic Malignancies, Snowbird, UT3/18/2012 “Adoptive Cell Therapy: Utilizing the Immune System to combat Cancer” &“Genetically Targeted T cells in Cancer Immunotherapy: the past, the present, andthe future”, Innovations in Oncology – Targeted Therapies and Cancer Program,Delhi, India4/13/2012 “Adoptive Therapy of Cancer of Cancer using Tumor Targeted T-cells: A GeneticApproach, Medical Grand Rounds at Roswell Park Cancer Institute, Buffalo, NY6/2/2012 Discussant, Poster Discussion Session – Developmental Therapeutics-ClinicalPharmacology and Immunotherapy Track, American Society of ClinicalOncology 48 th Annual Meeting, Chicago, IL6/6/2012 “Clinical Translation of an Adoptive Therapeutic Approach to Cancer: Obstaclesfrom the Perspective of an Academic Investigator”, International Society of CellTherapy 18 th Annual Meeting, Seattle, WA6/8/2012 “Chimeric Antigen Receptor (CAR) modified T cells as a novel approach toimmuno-therapy of B cell malignancies”, International Society of Cell Therapy18 th Annual Meeting, Seattle, WA9/9/2012 “CAR modified T cell therapy: Future directions and moving beyond the singlecenter setting”, 10 th International Workshop on Non-Hodgkin Lymphoma,Boston, MA12

10/19/2012 “Chimeric antigen receptor (CAR) modified T cells as a novel approach to cancerimmunotherapy: Initial promising clinical responses and future directions”,Japanese Society of Hematology 74 th Annual Meeting, Kyoto, Japan11/7/2012 “Treatment of Cancer with Genetically Modified T-cells”, ChemotherapyFoundation Symposium on Innovative Cancer Therapy for Tomorrow,Hematology Session, Mount Sinai School of Medicine, New York, NY11/27/2012 “Chimeric Antigen Receptor Expressing T cells (CARETS): A CurativeImmunotherapy Platform for Adoptive T Cell Therapy of Cancer”, NYCEmerging Technologies Summit, New York, New York12/8/2012 “Novel Cellular Therapies for Leukemia: CAR-Modified T-Cells Targeted to theCD19 Antigen”, American Society of Hematology 54 th Annual Meeting, Atlanta,Georgia12/21/2012 “CAR Modified T-Cells and Cancer Therapy”, Memorial Sloan-Kettering CancerCenter Medicine Grand Rounds, New York, NY2/14/2013 “Adoptive Therapy of Cancer with Genetically Modified T Cells”, 4 th AnnualConference on Cancer Biologics part of Cambridge Healthtech Institute’s 20 thInternational Molecular Medicine Tri-Conference, San Francisco, CaliforniaEditorial responsibilitiesJournal name (ad hoc reviewer vs Editorial Board with position as applicable)Journal Reviewer:BloodJournal of Clinical InvestigationJournal of Clinical OncologyJournal of ImmunologyCancer Immunology and ImmunotherapyCancer ResearchClinical Cancer ResearchClinical LeukemiaMolecular TherapyGene TherapyAmerican Journal of HematologyExperimental HematologyBMC ImmunologyPLoS ONEPNASNature Reviews Clinical OncologyHaematologicaEuropean Journal of Immunology13

Editorial Advisory Board:Reviews on Recent Clinical TrialsClinical Cancer Research (American Association for Cancer Research)Study section peer review activitiesDateActivity2009 Reviewer, NIH ZRG1 BDA-A (52) study section2009 Reviewer, Terry Fox New Frontiers Program in Cancer2012 External Peer Reviewer, British Lung Foundation2012 External Peer Reviewer, Swiss Cancer LeagueOther consultant activities or positionsDateActivity2009-2011 Member, Junior Investigator Task Force, American Society of Gene and CellTherapy (ASGCT)2010-presentMember, Cancer Gene and Cell Therapy Committee, American Society ofGene and Cell Therapy (ASGCT)2010-2012 Member, Website Task Force, American Society of Gene and Cell Therapy(ASGCT)2011-presentMember, Scientific Program Committee, American Society of ClinicalOncology (ASCO)5/17/10 - 5/22/10 Abstract Reviewer, American Society of Gene and Cell Therapy (ASGCT)Annual Meeting: “Immunologic and Host Responses in Gene and Cell Therapy”Track, ASGCT 13 th Annual Meeting, Washington DC6/1/12 - 6/5/12 Abstract Reviewer, American Society of Clinical Oncology (ASCO) AnnualMeeting: “Developmental Therapeutics – Clinical Pharmacology andImmunotherapy” Track, ASCO 48 th Annual Meeting, Chicago, IL5/15/13 - 5/18/13 Abstract Reviewer, American Society of Gene and Cell Therapy (ASGCT)Annual Meeting: “Immunologic and Host Responses in Gene and Cell Therapy”Track, ASGCT 16 th Annual Meeting, Salt Lake City, Utah14

L. BIBLIOGRAPHY1. Brentjens RJ, Spinola SM, Campagnari AA. Haemophilus ducreyi adheres to keratinocytes. MicrobialPathogen. 16:263-267, 1994. PMID: 80900822. Brentjens RJ, Ketterer M, Apicella MA, Spinola SM. Fine tangled pili expressed by Haemophilus ducreyiare a novel class of pili. J. Bact. 178:808-816, 1996. PMID: 85505173. Brentjens RJ, Smith L, Reich L, Jakubowski AA. Development of spontaneous factor VIII inhibitor inassociation with acute graft versus host disease. Bone Marrow Trans. 27:887-889, 2001. PMID: 114774494. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T lymphocyte cytotoxicity and proliferationdirected by a single chimeric TCRζ/CD28 receptor. Nat. Biotech. 20:70-75, 2002. PMID: 117533655. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, RiviereI, Sadelain M. Eradication of systemic B cell tumors by genetically targeted human T lymphocytes costimulatedby CD80 and interleukin-15. Nat. Med. 9:279-286, 2003. PMID: 125791966. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M,Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Riviere I, Larson SM, Koutcher JA,Sadelain M. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. CancerRes. 65(19):9080-8, 2005. PMID: 162040837. Lammana N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, GencarelliA, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active,well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol.24(10):1575-81, 2006. PMID: 165204648. McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, BrentjensR, Scheinberg DA. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nuc Med48(7):1180-9, 2007. PMID: 176070409. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintas-Cardama A, Larson S,Sadelain M. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts bygenetically targeted T cells. Clin Can Res 13(18): 5426-35, 2007. PMID: 1785564910. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell encodedCD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13(12):1440-9, 2007. PMID: 1802611511. Quintas-Cardama A, Yeh RK, Hollyman D, Stefanski J, Nikhamin Y, Imperato G, Sadelain M, Riviere I,Brentjens RJ. Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes forclinical application. Hum Gen Ther 18(12): 1253-60, 2007. PMID: 1805271912. Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg JM, Jenk R, Holland AM, Gurbin J,Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant-Angelo DB, Riviere I, Sadelain M, Heller G, Zuniga-Pflucker JC, Lu C, van den Brink MR. Tumor immunotherapy across MHC barriers using allogeneic T cellprecursors. Nat Biotech 26 (4):453-61, 2008. PMID: 1837639915

13. Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, GoldeDW, Scheinberg DA, Zelenetz AD, Weiss MA. Sequential therapy with fludarabine, high-dosecyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemiaproduces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol27(4): 491-7, 2009. PMID: 1907528014. Santos EB, Yeh R, Lee J, NIkhamin Y, Punzalan B, Punzalan B, La Perle K, Larson SM, Sadelain M,Brentjens RJ. Sensitive in vivo imaging of T cells utilizing a membrane bound Gaussia princeps luciferase.Nat Med 15 (3):338-44, 2009. PMID: 1921902315. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V,Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Riviere I. Manufacturing validation of biologicallyfunctional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32: 169-80,2009. PMID: 1923801616. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia withgenetically targeted autologous T cells: A case report of an unforeseen adverse event in a phase I clinical trial.Mol Ther 18:666-8, 2010. PMID: 2035777917. Na IK, Markley JC, Tsai JJ, Yim NL, Beattie BJ, Klose AD, Holland AM, Ghosh A, Rao UK, Stephan MT,Serganova I, Santos EB, Brentjens RJ, Blasberg RG, Sadelain M, van den Brink MR. Concurrentvisualization of T lymphocytes and T cell precursors in vivo. Blood. 2010 Sep 16;116(11):e18-25. Epub 2010May 28. PMID: 2051154118. Lee J, Hayman E, Pegram H, Santos E, Heller G, Sadelain M, Brentjens RJ. In vivo inhibition of humanCD19 targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cellmalignancy. Can Res (in press).19. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, Brentjens RJ. Successfuleradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cellsgenetically targeted to the MUC16 antigen. Clin Can Res 16:3594-606, 2010 PMID: 2062803020. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M. CARson Track in the Clinic. Heslop HE. Mol Ther. 2011 Mar;19(3):432-8. PMID: 2135870521. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. In vivo Inhibition of HumanCD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B CellMalignancy. Cancer Res. 2011 Apr 15;71(8):2871-81. Epub 2011 Apr 12. PMID: 2148703822. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, HoseyJ, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safetyand persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed orchemotherapy refractory B-cell leukemias. Blood. 2011 Nov 3;118(18):4817-28. Epub 2011 Aug 17. PMID:2184948623. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ.Tumor-targeted T cellsmodified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012 Feb 21.[Epub ahead of print] PMID:2235400116

1. Books, book chapters and reviews1. Brentjens RJ, Saltz L. Islet cell tumors of the pancreas: The medical oncologist’s perspective. Surg. Clin.North Am. 81:527-542, 2001. PMID: 114592692. Brentjens R, Saltz L. Epidermal growth factor receptor blockade and the treatment of solid tumormalignancies. In Progress in Oncology 2002. VT DeVita, S Hellman, SA Rosenberg, eds. Sudbury: Jonesand Bartlett Publishers, 2003:113-128.3. Sadelain M, Riviere I, and Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat.Rev. Can. 3:35-45, 2003. PMID: 125097654. Brentjens R, Sadelain M. Somatic cell engineering and the Immunotherapy of Leukemias and Lymphomas.Advances Pharmacol. 51:347-70, 2004. PMID: 154649175. Riviere I, Sadelain M, Brentjens R. Novel Strategies for cancer therapy: The potential of genetically modifiedT lymphocytes. Curr Hematol Rep 3:290-297, 2004. PMID: 152175596. Brentjens R, Weiss M. Chronic leukemias. In Conn’s Current Therapy. Rakel, Bope eds. Philadelphia:Elsevier, 2005: 514-521.7. Brentjens R. Novel approaches to immunotherapy for B cell malignancies. Curr Oncol Rep. 6(5):339-47,2004. [Reprinted in Curr Hematol Rep. 2005 Jan;4(1):64-72]. PMID: 152919748. Brentjens RJ. Novel approaches to immunotherapy for B cell malignancies: An update. Curr. Hematol.Malig. Rep. 1, 258-63, 2006. PMID: 20453219. Lee J, Sadelain M, Brentjens R. Retroviral transduction of murine primary T cells. Methods in MolecularMedicine 506:83-96, 2009. PMID: 1911062110. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr.Opin. Immunology 21:1-9, 2009. PMID: 1932797411. Brentjens R. Cellular therapies in acute lymphoblastic leukemia. Curr. Opin. Mol. Ther. 11:375-82, 2009.PMID: 1964998212. Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients withovarian cancer. Discov Med. 9:62-70 2010. PMID: 2010268813. Park J, Brentjens RJ. Adoptive immunotherapy for B cell malignancies with autologous chimeric antigenreceptor modified tumor targeted T cells. Discov Med 9:277-88 2010. PMID: 2042367114. Park JH, Sauter C, Brentjens R. Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol ClinNorth Am. 2011 Dec; 25(6):1281-301. [PubMed - indexed for MEDLINE] PMID: 2209358715. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: currentunderstanding and future direction. J Gene Med. 2012 Jun;14(6):405-15.doi: 10.1002/jgm.2604. PMID:2226264917

16. Brentjens RJ.CARs and cancers: questions and answers. Blood. 2012 Apr 26;119(17):3872-3.PMID:2253849317. How do CARs work? : Early insights from recent clinical studies targeting CD19.Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. Oncoimmunology. 2012 Dec 1;1(9):1577-1583.PMID: 23264903[PubMed]2. Abstracts (Optional, not encouraged)1. R. Brentjens, M. Gong, J.B. Latouche, I. Riviere, M. Sadelain. Long Term Survival of SCID-Beige Micebearing Raji Cell Tumors After Intravenous Treatment with Human T Cells Genetically Modified to Recognizethe CD19 Antigen [Abstract]. Blood. 2001; 98: 694a.2. R. Brentjens, J.B. Latouche, M. Weiss, I. Riviere, M. Sadelain. Genetic Modification of Peripheral Blood TCells from Patients with Chronic Lymphocytic Leukemia Results in Cytotoxic Activity Against AutologousTumor Cells [Abstract]. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002; 21: 276a.3. R. Brentjens, J.B. Latouche, I. Riviere, M. Weiss, M. Sadelain. Eradication of Systemic CD19+ Tumors inSCID-Beige Mice by Intravenous Treatment with Human CD8+ T Cells Genetically Modified to Recognize theCD19 Antigen [Abstract]. Mol. Ther. 2002; 5: S441. (ORAL PRESENTATION)4. R. Brentjens, J.B. Latouche, I. Riviere, M. Sadelain. In Vivo Anti-Tumor Activity of Genetically Modified TCells is Dependent on the Method of Ex Vivo T Cell Expansion [Abstract]. Blood. 2002; 100: 577a.5. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Riviere I,Sadelain M. Eradication of Systemic B cell Tumors by Genetically Targeted Human T Lymphocytes Co-Stimulated by CD80 and Interleukin-15 [Abstract]. Keystone Symposia 2003, Basic Aspects of TumorImmunology. Poster #439.6. R. Brentjens, M. Weiss, M. Sadelain. Genetic Modification of Autologous Peripheral Blood T Cells: AFeasible Immuno-Therapeutic Approach for the Treatment of Chronic Lymphocytic Leukemia (CLL)[Abstract]. 10 th International Workshop on CLL. Leuk. Lymph. 2003; 44(Supplement 2): S50. (ORALPRESENTATION)7. R. Brentjens, Y. Nikhamin, M. Matsushita, M. Sadelain. In Vitro and In Vivo Characterization of “Second-Generation” Co-Stimulatory Chimeric Antigen Receptors (CARs) Targeting the CD19 Antigen Present on BCell Malignancies [Abstract] Mol. Ther. 2005; 11: S311. (ORAL PRESENTATION)8. J. Stefanski, R. Brentjens, M. Bonyhadi, M. Sadelain, I. Rivière. Transduction and Expansion of TLymphocytes Genetically Engineered To Target the CD19 Antigen for the Treatment of CLL Using XcyteDynabeads®[Abstract] Mol. Ther. 2005; 11: S274.9. Lamanna, M. Kalaycio, P. Maslak, M. Heaney, R. Brentjens, J. Jurcic, E. Biederman, A. Gencarelli, K.Panageas, D. Sheinberg, M. Weiss. Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has ComparableActivity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) inPatients with Previously Treated Chronic Lymphocytic Leukemia [Abstract]. Blood, 2005; 106: 601a.10. J. Stefanski, R. Brentjens, D. Hollyman, M. Bonyhadi, M. Sadelain, I. Riviere. CD19-Targeted Normal andCLL Patient T cells Expanded with Beads Can Eradicate Systemic Tumors In Vivo. [Abstract]. Mol. Ther.2006; 13: S102.18

11. R. Brentjens, E. Santos, R. Yeh, K. La Perle, R. Toledo-Crow, Y. Nikhamin, B. Punzalan, D. Entenberg, I.Aranda, B. Punzalan, S. Larson, M. Sadelain. Sensitive In Vivo Detection of Primary T Cells ExpressingMembrane-Anchored Gaussia Luciferase for the Study of Adoptive T Cell Immunotherapy in Murine Modelsof Malignancy [Abstract]. Blood, 2006; 108: 3685a.12. R Brentjens; E Santos; Y Nikhamin; R Yeh; M Matsushita; K La Perle; A Quintas-Cardama; S Larson; MSadelain Successful eradication of systemic acute lymphoblastic leukemia xenografts by genetically targeted Tcells is limited by in vivo T cell co-stimulation and persistence. [Abstract]. Keystone Symposia 2007, PotentNew Anti-tumor Therapies. Poster #123.13. I Riviere, D Hollyman, J Stefanski, M Przybylowski, V Capacio, O Borquez-Ojeda, S Bartido, J Hosey, MSadelain, R Brentjens. CD19-targeted CLL patient T cells expanded with beads eradicate systemic B celltumors in vivo [Abstract]. Keystone Symposia 2007, Potent New Anti-tumor Therapies. Poster #305.14. J Lee, Y Nikhamin, R Brentjens. Functional Characterization of Genetically Modified Tumor-TargetingRegulatory T Cells [Abstract]. World Immune Regulation Meeting 2007. Poster #241.15. D Hollyman, J Stefanski, M Przybylowski, S Bartido, O Borquez-Ojeda, V Capacio, K Smith, J Hosey, CTaylor, R Brentjens, M Sadelain, I Reviere. Validation of a large scale semi-closed system for themanufacture of autologous T cells genetically targeted to the B cell specific antigen CD19 for a phase I trial inpatients with chronic lymphocytic leukemia [Abstract] Mol Ther. 2007;15:S165.16. R Brentjens, E Santos, R Yeh, Y Nikhamin, K LaPerle, S Larson, M Sadelain. Utilization of a novel luciferaseconstruct to demonstrate trafficking of genetically targeted CD19 specific T cells to systemic human acutelymphoblastic leukemia in a mouse [Abstract]. Mol Ther. 2007;15:S22417. R. Brentjens, I. Rieviere, D. Hollyman, J. Stefanski, M. Przybylowski, S. Bartido, O. Borquez-Ojeda, C.Taylor, J.Hosey, M. Heaney, M. Weiss, M. Sadelain. A phase I trial for the treatment of purine analoguerefractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specificantigen CD19 [Abstract]. 12 th International Workshop on CLL. Leuk. Lymph. 2007; 48(Supplement 1): S173.18. James Lee, Yan Nikhamin, Gavin Imperato, Adam Cohen, Michel Sadelain, and Renier J. Brentjens. Efficacyand Long Term Survival of Genetically Modified T cells Targeting CD19 in a Syngeneic Immune CompetentTransgenic Murine Tumor Model is Dependent on Prior Lymphodepleting Chemotherapy. Blood 2007; 10919. RJ Brentjens, D Hollyman, M Weiss, J Stefanski, M Przybylowski, S Bartido, O Borquez-Ojeda, C Taylor, JHosey, M Heaney, M Sadelain, I Riviere. A Phase I Trial for the Treatment of Chemo-Refractory ChronicLymphocytic Leukemia with CD19-Targeted Autologous T cells. [Abstract: Oral Presentation] Mol. Ther.2008;16:S1 ( Oral Presentation #38)20. J Lee, M Sadelain, RJ Brentjens. Tumor-targeted human CD4+ CD25 hi regulatory T cells effectively inhibit Tcell mediated rejection of CD19+ tumors in an in vivo xenotransplant tumor model [Abstract] Blood 2008; 112:poster 3901.21. J Lee, M Sadelain, RJ Brentjens. Tumor Targeted T cells modified to express IL-12 overcome inhibitionmediated by the hostile tumor microenvironment [Abstract]. Keystone symposia 2009, Mobilizing CellularImmunity for Cancer Therapy (A3). Snowbird UT, 1/11-1/16/09.22. J Lee, M Sadelain, RJ Brentjens. Tumor-targeted T cells modified to expressIL-12 overcome inhibitionmediated by the hostile tumor microenvironment [Abstract] Mol Ther 2009; 17:S8919

23. RJ Brentjens, I Riviere, D Hollyman, C Taylor, Y nikhamin, J Stefanski, J Lee, R Yeh, E Santos, M Sadelain.Unexpected toxicity of cyclophosphamide followed by adoptively transferred CD19-targeted T cells in a patientwith bulky CLL [Abstract: Oral Presentation] Mol Ther 2009; 17:S15724. AA Chekmasova, Y Nikhamin, D Thapi, DR Spriggs, RJ Brentjens. Genetically modified human T cellstargeted to retained epitopes of the MUC-16 antigen are functional and mediate lysis of ovarian tumor celllines. [Abstract] Mol Ther 2009; 17:S21325. C Taylor, D Hollyman, M Olszewska, RJ Brentjens, M Sadelain, I Riviere. Validation of flow cytometry andQ-PCR assays for the detection of genetically modified T cells in the peripheral blood of patients. {Abstract}Mol Ther 2009; 17:S22126. RJ Brentjens., D Hollyman, J Park, E Santos, R Yeh, J Stefanski, C Taylor, MA Weiss, D Filippa, I Riviere, MSadelain. Enhanced in vivo activation of adoptively transferred genetically targeted T cells followingcyclophosphmaide chemotherapy: Initial results from a phase I clinical trial treating CLL patients withautologous CD19-targeted T cells. [Abstract] ASH Meeting, New Orleans, LA Dec 5-8, 2009. Blood 2009,114:1335.27. AA Chekmasova, TD Rao, DR Spriggs, RJ Brentjens. Adoptive transfer of T cells genentically targeted to theMUC16 antigen eradicates established peritoneal ovarian tumors in SCID-Beige mice. [Abstract] ASGCT 2010meeting in Washington DC May 17-22. Mol Ther 2010, 18:S70.28. KJ Curran, R Yeh, B Seinstra, Y Nikhamin, Y Usachenko, RJ Brentjens. Genetically mediated constitutiveexpression of CD40L by T cells will induce enhanced immunogenicity of B cell malignancies. [Abstract]ASGCT 2010 meeting, Washington DC May 17-22. Mol Ther 2010, 18:S315.29. RJ Brentjens, I Riviere, M Frattini, X Wang, C Taylor, M Olszewska, O Borquez-Ojeda, S Bartido, JStefanski, R Yeh, M Sadelain. Marked regression of adenopathy following infusion of autologous T cellsgenetically targeted to the CD19 antigen in a patient with bulky CLL. [Abstract: Oral Presentation] ASGCT2010 meeting, Washington DC May 17-22. Mol Ther 2010, 18:S14.30. J. H. Park, R. Yeh, I. Rivère, M. Sadelain and R. J. Brentjens. In vitro analysis of suicide gene expression andfunction in human T lymphocytes transduced to express a tumor-targeted chimeric antigen receptor. AmericanSociety of Clinical Oncology (ASCO) 46 th Annual Meeting, June 2010, Chicago, IL.31. K.J. Curran, C. Taylor, E. Doubrovina, X. Wang, R. J. O'Reilly, M. Sadelain, N. A. Kernan, R.J. Brentjens,and I. Rivière. Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen EradicatesSystemic Lymphoma In Mice (Abstract #2092). 52 nd ASH Annual Meeting, December, 2010, Orlando, FL.32. E. Hayman, J. Lee, H. J. Pegram, R. Brentjens. Adoptive Therapy with Human CD19 (hCD19)-Targeted TCells Further Modified to Express IL-12 Overcome the Need for Prior Lymphodepletion to EradicateEstablished hCD19 + Tumors and Induce B Cell Aplasias In Immune Competent hCD19 + TransgenicMice(Abstract # 2097). 52 nd ASH Annual Meeting, December, 2010, Orlando, FL.33. J.J. Harding, R. Yeh, Y. Nikhamin, M. Frattini, N. Lamanna, J. G Jurcic, M. Heaney, R.Brentjens.Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic LymphocyticLeukemia (Abstract # 3595). 52 nd ASH Annual Meeting, December, 2010, Orlando, FL.34. H. J. Pegram, V.LaRussa, R. Brentjens. CD19 Targeted Cord Blood Derived T Cells for CancerImmunotherapy (Abstract # 3767). 52 nd ASH Annual Meeting, December, 2010, Orlando, FL.20

35. M.L. Davila, C.Taylor, X.Wang, J. Stefanski, M. Olszewska, S. Bartido, M. Frattini, M. Sadelain, I. Rivière,R.J. Brentjens. B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia FollowingRe-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen (Abstract# 3268). 52 nd ASH Annual Meeting, December 2010 Orlando, FL.36. J. H. Park, R. Yeh, I. Rivière, M. Sadelain, and R. J. Brentjens. In Vitro analysis of Suicide Gene Expressionand Function of 3 Suicide Gene-Prodrug Combinations In Human T Lymphocytes Further Modified to Expressthe CD19 Targeted 19-28z Chimeric Antigen Receptor (Abstract # 3771). 52 nd ASH Annual Meeting,December 2010, Orlando, FL.37. K. Curran, C. Taylor, E. Doubrovina, X. Wang, R. O’Reilly, M. Sadelain, N. Kernan, R.J. Brentjens, I. Rivère.Validation of Donor Derived Virus Specific T-Lymphocytes Genetically Modified To Target the CD19 Antigenfor the Treatment of Relapsed Leukemia (Abstract # 230). American Society of Gene and Cell Therapy(ASGCT) 14 th Annual Meeting, May 18 – 22, 2011, Seattle, WA.38. H.J. Pegram, V. La Russa, R.J. Brentjens. Expansion and Anti-Tumor Efficacy of CD19 Targeted Cord BloodT Cells (Abstract # 239). American Society of Gene and Cell Therapy (ASGCT) 14 th Annual Meeting, May 18– 22, 2011, Seattle, WA.39. A.A. Chekmasova, S. Sandadi, Y. Nikhamin, D.R. Spriggs, R.J. Brentjens. Effective Eradication ofEstablished Ovarian Murine Tumors with MUC16 Targeted T Cells Expressing IL-12 Gene (Abstract # 495).American Society of Gene and Cell Therapy (ASGCT) 14 th Annual Meeting, May 18 – 22, 2011, Seattle, WA.40. T. Tsukahara, K. Ohmine, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, I. Rivère, M. Sadelain, R.J.Brentjens, K. Ozawa. Anti-Tumor Activity of Engineered T Lymphocytes Expressing an Anti-CD19 CAR forB Cell Lymphoma (Abstract # 791). American Society of Gene and Cell Therapy (ASGCT) 14 th AnnualMeeting, May 18 – 22, 2011, Seattle, WA.41. R. J. Brentjens, I. Riviere, J. Park, M. Davilla, X. Wang, R. Yeh, N. Lamanna, M. G. Frattini, M. Sadelain.Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated withautologous, CD19-targeted T cells (Abstract# 2534). American Society of Clinical Oncology (ASCO) 47 thAnnual Meeting, June 3 – 7, 2011, Chicago, IL.42. J R Gardner, K. Knapp, M.G. Frattini, N. Lamanna, R. Brentjens, J.G Jurcic, P G. Maslak, E. Berman,M..Weiss, D. A. Scheinberg, M. Heaney. Elevated Mitochondrial Membrane Potential in CLL Cells IsAssociated with a more aggressive Natural History (Abstract # 1765). American Society of Hematology (ASH)53 rd Annual Meeting, Dec. 10 – 13, 2011, San Diego, CA.43. H. J. Pegram, J. Lee, E. Hayman, G. H Imperato, T. J. Tedder, R. J Brentjens. Tumor Specific T CellsModified to Secrete IL-12 Eradicate Systemic Tumors in the Absence of Prior Toxic ChemotherapyConditioning Regimens. (Abstract # 3120). American Society of Hematology (ASH) 53 rd Annual Meeting, Dec.10 – 13, 2011, San Diego, CA.44. J. H. Park, R. Yeh, I. Riviere, M. Sadelain, R. Brentjens. In Vivo comparison of 3 Suicide Gene-ProdrugCombinations in a Mouse Graft-Versus-Host-Disease Model (Abstract # 3121). American Society ofHematology (ASH) 53 rd Annual Meeting, Dec. 10 – 13, 2011, San Diego, CA.45. A. A Chekmasova, S. Sandadi, D. R Spriggs, R. J Brentjens. Enhanced Antitumor Efficacy of MUC-16Targeted T Cells Further Modified to Constitutively Express the IL-12 Cytokine in a Syngeneic Model ofOvarian Cancer. (Abstract # 4176). American Society of Hematology (ASH) 53 rd Annual Meeting, Dec. 10 –13, 2011, San Diego, CA.21

46. T. Tsukahara, K. Ohmine, R. Uchibori, H. Ido, M. Urabe, H. Mizukami, A. Kume, M. Nakamura, I. Rivère, M.Sadelain, R.J. Brentjens, K. Ozawa. Evaluation of Anti-Tumor Effects Mediated by Engineered TLymphocytes Expressing a CD19 Specific CAR for B Cell Lymphoma (Abstract # 677). American Society ofGene and Cell Therapy (ASGCT) 15 th Annual Meeting, May 16 – 19, 2012, Philadelphia, PA.47. A.A. Chekmasova, S. Sandadi, D.R. Spriggs, R.J. Brentjens. Effect of modulation of the hostile tumormicroenvironment through adoptive transfer of IL-12 expressing MUC-16 targeted T cells on ovarian tumors invivo (Abstract# 2586). American Society of Clinical Oncology (ASCO) 48 th Annual Meeting, June 1 – 5, 2012,Chicago, IL.48. M.L. Davila, I. Riviere, X. Wang, S. Bartido, J. Stefanski, C. Taylor, M. Olszewska, O. Borquez-Ojeda, J. Qu,T. Waisielewska, M. G. Frattini, M. Sadelain, R.J Brentjens. A Phase I Clinical Trial of Autologous, anti-CD19 gene targeted T cells for adults with B Cell acute lymphoblastic Leukemia (B-ALL) (Abstract#TPS2619). American Society of Clinical Oncology (ASCO) 48 th Annual Meeting, June 1 – 5, 2012, Chicago,IL.49. S. Mathew, S. Harnicar, E. Halton, E. Berman, R.J Brentjens, M.L. Heaney, J.G. Jurcic, N. Lamanna, P.G.Maslak, T.L. Rosenblat, N.G. Adel, M.G. Frattini. Safety and efficacy of dose escalated liposomal amphotericinB in adult leukemia patients with refractory invasive fungal infections: A single institution report (Abstract#6613). American Society of Clinical Oncology (ASCO) 48 th Annual Meeting, June 1 – 5, 2012, Chicago, IL.50. J.H. Park, I.Rivière, X.Wang, J.Stefanski, Q. He, C. Taylor, M. Olszewska, T. Wasielewska, S. Bartido, M. LDavila, Y. Bernal, N. Lamanna, A. Noy, M. Sadelain, R. J Brentjens. Impact of the ConditioningChemotherapy on Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of AutologousCD19-Targeted T Cells for Patients with Relapsed CLL (Abstract# 1797). American Society of Hematology(ASH) 54 th Annual Meeting, Dec. 8 – 11, 2012, Atlanta, Georgia51. H.J. Pegram, J. Barker, S.Giralt, R. J Brentjens. Expansion and Modification of Umbilical Cord Blood T Cellswith a Chimeric Antigen Receptor and IL-12 (Abstract# 1907). American Society of Hematology (ASH)54 thAnnual Meeting, Dec. 8 -11, 2012, Atlanta, Georgia52. J. R Gardner, S.Devlin, K. Knapp, F. Bauli, N. Lamanna, M.G. Frattini, R.J Brentjens, P. G. Maslak, J.G.Jurcic, M. Weiss, D.A. Scheinberg, M. Heaney. Aerobic Glycolysis Predicts Outcome in Early ChronicLymphocytic Leukemia. (Abstract#2482). American Society of Hematology (ASH)54 th Annual Meeting, Dec. 8-11, 2012, Atlanta, Georgia53. N. Terziyska, C. Castro Alves, M. Ogris, E. Wagner, R.J Brentjens, M.A. Horstmann, L. Quintanilla-Martinez,I. Jeremias. Highly Sensitive Bioluminescence in Vivo ImagingEnables Individualized Preclinical Treatment Trials on Patients ALL Tumor Cells Growing in Mice (Abstract#2602). American Society of Hematology (ASH)54 th Annual Meeting, Dec. 8 -11, 2012, Atlanta, Georgia54. M. L Davila, C. Kloss, R. J Brentjens, M.Sadelain. Conditioning Intensity and T Cell Dose DetermineEfficacy of CD19- Targeted T Cell-Mediated Tumor Eradication in an Immunocompetent Mouse Model of B-ALL (Abstract# 2613). American Society of Hematology (ASH)54 th Annual Meeting, Dec. 8 -11, 2012,Atlanta, Georgia55. K J. Curran, N. A. Kernan, X. Wang, C. Taylor, E. Doubrovina, S. Bartido, M. Sadelain, ,R. J. O'Reilly, R.JBrentjens, I. Rivière.CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL inPediatric Patients Post HSCT (Abstract# 353). American Society of Hematology (ASH) 54 th Annual Meeting,Dec. 8 -11, 2012, Atlanta, Georgia22

56. E. Halton, D. Chung, K. Xiao, H. Quintanilla, C. Baldwin, , P. Baird, E. Berman, R.J Brentjens, M. Heaney,J.G. Jurcic, N. Lamanna, T.L. Rosenblat, R.Kaplan, G. Papanicolaou, M.G. Frattini. Micafungin VersusPosaconazole Anti-Fungal Prophylaxis In Adult Patients with Acute Leukemia Undergoing InductionChemotherapy (Abstract# 3556). American Society of Hematology (ASH)54 th Annual Meeting, Dec. 8 -11,2012, Atlanta, Georgia57. M. L Davila, I. Riviere, X. Wang, J. H. Park, J. Stefanski , C. Taylor, Q. He, M. Olszewska, T. Wasielewska, O.Borquez-Ojeda, J. Qu, S. Bartido, J.G. Jurcic, D. Douer, M. G. Frattini, M. Sadelain, R. J Brentjens . MolecularRemission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19-28zCAR-Targeted T Cells (Abstract# 3566). American Society of Hematology (ASH)54 th Annual Meeting, Dec. 8-11, 2012, Atlanta, Georgia58. K. J. Curran, B. Seinstra, Y. Nikhamin, R. Yeh, Y. Usachenko, R. J Brentjens . . Constitutive Expression ofCD40L by CAR-Modified Tumor Targeted T Cells Enhances Anti-Tumor Efficacy Both in Vitro and in Vivo(Abstract# 4120). American Society of Hematology (ASH)54 th Annual Meeting, Dec. 8 -11, 2012, Atlanta,Georgia59. R. Brentjens, M. Davila; J. Park; I. Riviere; X. Wang; M. Frattini, M. Sadelain. Rapid Molecular Remissionand B Cell Aplasia Induced by CD19-Targeted T Cells in Adult Patients with B Cell Acute LymphoblasticLeukemia (B-ALL) (Abstract# 1012). Keystone Symposia 2013 : Cancer Immunology and Immunotherapy,Jan. 27 – Feb. 1 2013, Vancouver, British Columbia, Canada3. Presentations (Optional, not encouraged)Date: _____________________Signature:______________________________________23